Patients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnover

Journal of Bone and Mineral Research

Volumn 26, Issue 12, 2011, Pages 2804-2811

  Van Lierop, Antoon H ^a   Hamdy, Neveen A T ^a   Hamersma, Herman ^b   Van Bezooijen, Rutger L ^a   Power, Jon ^c   Loveridge, Nigel ^c   Papapoulos, Socrates E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Flora Clinic   (South Africa)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

BONE FORMATION; BONE RESORPTION; CARRIERS; SCLEROSTEOSIS; SCLEROSTIN

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; CROSS LINKED C TELOPEPTIDE; PHOSPHATE; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINO TERMINAL PROPEPTIDE; SCLEROSTIN; TELOPEPTIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CARRIER; DISEASE MODEL; DIZZINESS; FEMALE; GENE MUTATION; HEADACHE; HETEROZYGOTE; HUMAN; INTRACRANIAL HYPERTENSION; MALE; MORPHOMETRICS; NAUSEA; NEUROLOGIC EXAMINATION; OSSIFICATION; OSTEOSCLEROSIS; PHENOTYPE; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; SEX DIFFERENCE; SUBSTITUTION REACTION; VITAMIN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; CALCIUM; CASE-CONTROL STUDIES; CHILD; COLLAGEN TYPE I; FEMALE; GENETIC MARKERS; HETEROZYGOTE; HUMANS; HYPEROSTOSIS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; SYNDACTYLY; YOUNG ADULT;

EID: 81855180504     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.474     Document Type: Article

References (40)

1. Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL,. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int. 2010; 87: 99-107.
2. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den EJ, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W,. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10: 537-43. (Pubitemid 32184286)
3. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J,. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68: 577-89. (Pubitemid 32202753)
4. Piters E, Culha C, Moester M, Van Bezooijen R, Adriaensen D, Mueller T, Weidauer S, Jennes K, de Freitas F, Lowik C, Timmermans JP, Van Hul W, Papapoulos S,. First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function. Hum Mutat. 2010; 31: E1526-43.
5. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Lowik CW,. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004; 199: 805-14. (Pubitemid 38375200)
6. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D,. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280: 19883-7. (Pubitemid 41379516)
7. van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, Quax PH, Vrieling H, Papapoulos SE, ten Dijke P, Lowik CW,. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res. 2007; 22: 19-28. (Pubitemid 46032593)
8. Truswell AS,. Osteopetrosis with syndactyly; a morphological variant of Albers-Schonberg's disease. J Bone Joint Surg Br. 1958; 40-B: 209-18.
9. Hamersma H, Gardner J, Beighton P,. The natural history of sclerosteosis. Clin Genet. 2003; 63: 192-7. (Pubitemid 36949919)
10. Beighton P, Durr L, Hamersma H,. The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals. Ann Intern Med. 1976; 84: 393-7.
11. Gardner JC, van Bezooijen RL, Mervis B, Hamdy NA, Lowik CW, Hamersma H, Beighton P, Papapoulos SE,. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab. 2005; 90: 6392-5. (Pubitemid 41759290)
12. van Lierop AH, Witteveen JE, Hamdy NA, Papapoulos SE,. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol. 2010; 163: 833-7.
13. Weidauer SE, Schmieder P, Beerbaum M, Schmitz W, Oschkinat H, Mueller TD,. NMR structure of the Wnt modulator protein Sclerostin. Biochem Biophys Res Commun. 2009; 380: 160-5.
14. Zanelli JM, Pearson J, Moyes ST, Green J, Reeve J, Garrahan NJ, Stanton MR, Roux JP, Arlot ME, Meunier PJ,. Methods for the histological study of femoral neck bone remodelling in patients with fractured neck of femur. Bone. 1993; 14: 249-55. (Pubitemid 23175736)
15. Bell KL, Loveridge N, Power J, Rushton N, Reeve J,. Intracapsular hip fracture: increased cortical remodeling in the thinned and porous anterior region of the femoral neck. Osteoporos Int. 1999; 10: 248-57. (Pubitemid 29458721)
16. du Plessis JJ,. Sclerosteosis: neurosurgical experience with 14 cases. J Neurosurg. 1993; 78: 388-92. (Pubitemid 23073207)
17. Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH,. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011; 6: 877-82.
18. Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, Haibel H, Baraliakos X, Hempfing A, Rudwaleit M, Sieper J, Schett G,. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2009; 60: 3257-62.
19. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE,. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010; 95: 2248-53.
20. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA,. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010; 95: 1991-7.
21. Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ III, Khosla S,. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011; 26: 373-9.
22. Modder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S,. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2011; 26: 27-34.
23. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E,. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide. Osteoporos Int. 2011 Jan 11 [Epub ahead of print].
24. McNulty M, Singh RJ, Li X, Bergstralh EJ, Kumar R,. Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. J Clin Endocrinol Metab. 2011 May 4 [Epub ahead of print].
25. Beighton P,. Sclerosteosis. J Med Genet. 1988; 25: 200-3.
26. Lewiecki EM,. Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. Expert Opin Biol Ther. 2011; 11: 117-27.
27. Padhi D, Jang G, Stouch B, Fang L, Posvar E,. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011; 26: 19-26.
28. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C,. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009; 24: 578-88.
29. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty C,. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010; 25: 948-59.
30. Tian X, Jee WS, Li X, Paszty C, Ke HZ,. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone. 2011; 48: 197-201.
31. van Lierop AH, Hamdy NA, Papapoulos SE,. Glucocorticoids are not always deleterious for bone. J Bone Miner Res. 2010; 25: 2796-800.
32. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA,. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003; 22: 6267-76. (Pubitemid 37522584)
33. van Bezooijen RL, Bronckers AL, Gortzak RA, Hogendoorn PC, Wee-Pals L, Balemans W, Oostenbroek HJ, Van Hul W, Hamersma H, Dikkers FG, Hamdy NA, Papapoulos SE, Lowik CW,. Sclerostin in mineralized matrices and van Buchem disease. J Dent Res. 2009; 88: 569-74.
34. Chun JS, Oh H, Yang S, Park M,. Wnt signaling in cartilage development and degeneration. BMB Rep. 2008; 41: 485-94.
35. Epstein S, Hamersma H, Beighton P,. Endocrine function in sclerosteosis. S Afr Med J. 1979; 55: 1105-10. (Pubitemid 9204269)
36. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C,. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23: 860-9. (Pubitemid 351768804)
37. Fujita K, Janz S,. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer. 2007; 6: 71.
38. Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G,. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005; 8: 751-64. (Pubitemid 40585297)
39. Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG,. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci. 2006; 119: 1283-96.
40. Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Latham JA,. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone. 2004; 35: 828-35. (Pubitemid 39349213)